Active, not recruitingPHASE1, PHASE2NCT03393884
Study of IMNN-001 (Also Known as GEN-1) With NACT for Treatment of Ovarian Cancer (OVATION 2)
Studying Primary peritoneal carcinoma
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Imunon
- Principal Investigator
- Premal H. Thaker, M.DWashington University School of Medicine
- Intervention
- IMNN-001(biological)
- Enrollment
- 130 target
- Eligibility
- 18 years · FEMALE
- Timeline
- 2018 – 2026
Study locations (21)
- University of Alabama Birmingham, Birmingham, Alabama, United States
- Mitchell Cancer Institute (University of South Alabama), Mobile, Alabama, United States
- Gynecologic Oncology Associates (Hoag Hospital), Newport Beach, California, United States
- Innovative Clinical Research, Whittier, California, United States
- Advent Health, Orlando, Florida, United States
- Women's Care Florida, St. Petersburg, Florida, United States
- Massachusetts General Hospital, Boston, Massachusetts, United States
- Washington University School of Medicine in St. Louis, St Louis, Missouri, United States
- MD Anderson at Cooper, Camden, New Jersey, United States
- Hackensack University Medical Center, Hackensack, New Jersey, United States
- Monter Cancer Center, Lake Success, New York, United States
- NYU Langone, Long Island, Mineola, New York, United States
- NYU Langone, New York, New York, United States
- Stephenson Cancer Center - Oklahoma University, Oklahoma City, Oklahoma, United States
- Providence Cancer Institute, Portland, Oregon, United States
- +6 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT03393884 on ClinicalTrials.govOther trials for Primary peritoneal carcinoma
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE1, PHASE2NCT07480954Dual-Targeting CAR-NK Cells for Recurrent Ovarian Cancer (MSLN, FRα, MUC16)Beijing Biotech
- RECRUITINGPHASE1, PHASE2NCT07322094CATALINA-4: A Study to Investigate the Safety and Efficacy of TORL-1-23 With Chemotherapy Given Before Initial Surgery in Women With Advanced Stage Ovarian CancerTORL Biotherapeutics, LLC
- RECRUITINGPHASE3NCT06915025Phase 3 Trial Evaluating the Safety & Efficacy of IMNN-001 Administered in Combination w/ Standard NACT & Adjuvant Chemotherapy in Newly Diagnosed Patients w/ Advanced EOC, Fallopian Tube or Primary Peritoneal CancerImunon
- RECRUITINGPHASE2NCT07023484Personalized Timing of Interval Debulking Surgery in Advanced Ovarian CancerThe University of Hong Kong
- RECRUITINGPHASE2NCT06639074Folate Receptor Alpha Dendritic Cells (FRαDCs) or Placebo for the Treatment of Patients With Stage III or IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer, FAROUT TrialMayo Clinic
- RECRUITINGPHASE1NCT06469281A Study to Learn if 27T51, a Mucin-16 (MUC16) Protein Targeting Immune Cell Therapy, Administered Alone or in Combination is Safe and How Well it Works for Adult Participants With Recurrent or Treatment Resistant Ovarian CancersRegeneron Pharmaceuticals
- RECRUITINGPHASE2NCT06492070Cryocompression With or Without Cilostazol for the Prevention of Paclitaxel-induced Neuropathy in Patients With Gynecological CancersEmory University
- RECRUITINGPHASE2NCT06434610A Study of B013 in Combination With Paclitaxel in Patients With Platinum-resistant Recurrent Ovarian Cancer.Shanghai Jiaolian Drug Research and Development Co., Ltd